Kamala Bhavaraju, Ph.D.

2010 Molecular and Cellular Physiology Temple University, Philadelphia, PA, United States 
Physiology Biology
"Kamala Bhavaraju"
Mean distance: (not calculated yet)


Sign in to add mentor
Satya P. Kunapuli grad student 2010 Temple University
 (Molecular physiology of thromboxane A2 generation.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bynagari-Settipalli YS, Lakhani P, Jin J, et al. (2012) Protein kinase C isoform ε negatively regulates ADP-induced calcium mobilization and thromboxane generation in platelets. Arteriosclerosis, Thrombosis, and Vascular Biology. 32: 1211-9
Bhavaraju K, Lakhani PR, Dorsam RT, et al. (2011) G(12/13) signaling pathways substitute for integrin αIIbβ3-signaling for thromboxane generation in platelets. Plos One. 6: e16586
Bhavaraju K, Georgakis A, Jin J, et al. (2010) Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Platelets. 21: 604-9
Bhavaraju K, Mayanglambam A, Rao AK, et al. (2010) P2Y(12) antagonists as antiplatelet agents - Recent developments. Current Opinion in Drug Discovery & Development. 13: 497-506
Garcia A, Kim S, Bhavaraju K, et al. (2010) Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. The Biochemical Journal. 429: 369-77
Bynagari YS, Nagy B, Tuluc F, et al. (2009) Mechanism of activation and functional role of protein kinase Ceta in human platelets. The Journal of Biological Chemistry. 284: 13413-21
Chari R, Getz T, Nagy B, et al. (2009) Protein kinase C[delta] differentially regulates platelet functional responses. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 699-705
Nagy B, Bhavaraju K, Getz T, et al. (2009) Impaired activation of platelets lacking protein kinase C-theta isoform. Blood. 113: 2557-67
Bhavaraju K, Kim S, Daniel JL, et al. (2008) Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. European Journal of Pharmacology. 580: 285-90
See more...